Hansoh stock forecast
Hansoh's weighted forecast reaches HKD30.98 in October 2029. It hinges on durable product growth and successful pipeline execution.
Where could Hansoh's shares go?
The probability-weighted forecast implies modest downside first, then recovery toward today’s price. The weighted price is HKD27.90 in October 2027, a negative 11% return including dividends. It rises to HKD29.35 in October 2028, still a negative 5% return. By October 2029, it reaches HKD30.98, a positive 2% return.
The weighted forecast points to modest downside before recovery toward today’s price by October 2029, hinging on durable product growth and successful pipeline execution.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 25 % | 17.87 (-42 %) | 15.54 (-49 %) | 12.94 (-56 %) |
| Base | 55 % | 28.12 (-10 %) | 28.17 (-8 %) | 28.15 (-6 %) |
| Bull | 20 % | 39.82 (+27 %) | 49.83 (+61 %) | 61.30 (+99 %) |
| Weighted | 100 % | 27.90 (-11 %) | 29.35 (-5 %) | 30.98 (+2 %) |
What has to go right for Hansoh, and what could go wrong?
This path reflects recent growth, but excludes the identified investment gain and assumes no conditional milestone becomes recurring profit. Innovative medicines and collaborative products were 82.2% of 2025 revenue, while oncology contributed 66.4%, so product growth is credible but concentrated. The bear case falls to CNY5,580m by 2029 as pricing, uptake and launches disappoint. The bull case reaches CNY10,080m if approvals and new indications make product growth outpace R&D and selling costs.
How much cash does Hansoh really make?
Operating cash flow starts with profit and adjusts for non-cash items and movements in items such as receivables, inventories and customer advances. Free cash flow goes further by deducting capital spending, lease payments and interest. The table’s “real” free cash flow also removes stock-based compensation, giving a stricter view of cash available to the business.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 6,738.246 | 3,862.355 | 3,116.468 | 2,741.205 | 2,577.062 |
| − Capital spending | 356.431 | 221.964 | 219.598 | 272.821 | 460.033 |
| = Free cash flow | 6,359.436 | 3,616.499 | 2,872.135 | 2,450.712 | 2,104.74 |
| − Stock pay | 143.268 | 137.725 | 171.365 | 179.416 | 65.472 |
| = Real free cash flow | 6,216.168 | 3,478.774 | 2,700.77 | 2,271.296 | 2,039.268 |
What this means. Real free cash flow is lower because it subtracts shares given to employees as pay, even though giving away shares does not use cash immediately.
What does an investor pay today for Hansoh?
The price-to-earnings ratio, or P/E, shows how much investors pay for each unit of profit. A forward P/E uses expected profit, so it is a forecast rather than a fact. The important question is what produces that profit. Product sales can recur as patients continue using medicines. Collaboration revenue usually comes from a licensing or partnership deal, while interest comes from investing cash. All three can raise accounting profit, but they do not carry the same promise of repetition.
| Today (Oct 18, 2026) | |
|---|---|
| Share price | 31.74 |
| Market value (calculated) | 192,476.123 |
| P/E, last 12 months (calculated) | 24.6x |
| P/E, next 12 months (calculated) | 23.6x |
| Free cash flow yield (calculated) | 3.9% |
What this means. The enterprise value is lower than the market value because the company has more cash than debt.